Erratum: Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy (Science Translational Medicine(2017) 9:418 (eaan8081) DOI: 10.1126/scitranslmed.aan8081);Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy

Science Translational Medicine

Volumn 9, Issue 418, 2017, Pages

  Amoasii, Leonela ^a   Long, Chengzu ^a,e   Li, Hui ^a   Mireault, Alex A ^a   Shelton, John M ^b   Sanchez Ortiz, Efrain ^a   McAnally, John R ^a   Bhattacharyya, Samadrita ^a   Schmidt, Florian ^c   Grimm, Dirk ^c   Hauschka, Stephen D ^d   Bassel Duby, Rhonda ^a   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; CASPASE 9; DYSTROPHIN; GENOMIC DNA; GUIDE RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; GENE DELETION; GENE EDITING; GENE MUTATION; HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; READING FRAME; SKELETAL MUSCLE; ANIMAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DISEASE MODEL; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROCEDURES;

ANIMALS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DISEASE MODELS, ANIMAL; DYSTROPHIN; EXONS; GENE EDITING; MICE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION;

EID: 85036640091     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aat0240     Document Type: Erratum

References (48)

1. K. F. O'Brien, L. M. Kunkel, Dystrophin and muscular dystrophy: Past, present, and future. Mol. Gen. Metab. 74, 75-88 (2001).
2. F. Muntoni, S. Torelli, A. Ferlini, Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740 (2003).
3. E. Mercuri, F. Muntoni, Muscular dystrophies. Lancet 381, 845-860 (2013).
4. K. P. Campbell, S. D. Kahl, Association of dystrophin and an integral membrane glycoprotein. Nature 338, 259-262 (1989).
5. J. M. Ervasti, K. Ohlendieck, S. D. Kahl, M. G. Gaver, K. P. Campbell, Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315-319 (1990).
6. S. Guiraud, A. Aartsma-Rus, N. M. Vieira, K. E. Davies, G.-J. B. van Ommen, L. M. Kunkel, The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genomics Hum. Genet. 16, 281-308 (2015).
7. J. R. Mendell, J. T. Kissel, A. A. Amato, W. King, L. Signore, T. W. Prior, Z. Sahenk, S. Benson, P. E. McAndrew, R. Rice, H. Nagaraja, R. Stephens, L. Lantry, G. E. Morris, A. H. M. Burghes, Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N. Engl. J. Med. 333, 832-838 (1995).
8. V. Arechavala-Gomeza, I. R. Graham, L. J. Popplewell, A. M. Adams, A. Aartsma-Rus, M. Kinali, J. E. Morgan, J. C. van Deutekom, S. D. Wilton, G. Dickson, F. Muntoni, Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798-810 (2007).
9. B. Wu, P. Lu, E. Benrashid, S. Malik, J. Ashar, T. J. Doran, Q. L. Lu, Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther. 17, 132-140 (2010).
10. J.-H. Shin, X. Pan, C. H. Hakim, H. T. Yang, Y. Yue, K. Zhang, R. L. Terjung, D. Duan, Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy. Mol. Ther. 21, 750-757 (2013).
11. Y. Yue, X. Pan, C. H. Hakim, K. Kodippili, K. Zhang, J.-H. Shin, H. T. Yang, T. McDonald, D. Duan, Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum. Mol. Genet. 24, 5880-5890 (2015).
12. J. Ramos, J. S. Chamberlain, Gene therapy for Duchenne muscular dystrophy. Expert Opin. Orphan Drugs 3, 1255-1266 (2015).
13. M. Le Hir, A. Goyenvalle, C. Peccate, G. Précigout, K. E. Davies, T. Voit, L. Garcia, S. Lorain, AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Mol. Ther. 21, 1551-1558 (2013).
14. J.-P. Iyombe-Engembe, D. L. Ouellet, X. Barbeau, J. Rousseau, P. Chapdelaine, P. Lagüe, J. P. Tremblay, Efficient restoration of the dystrophin gene reading frame and protein structure in DMD myoblasts using the CinDel method. Mol. Ther. Nucleic Acids 5, e283 (2016).
15. D. G. Ousterout, A. M. Kabadi, P. I. Thakore, W. H. Majoros, T. E. Reddy, C. A. Gersbach, Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 6, 6244 (2015).
16. C. Long, L. Amoasii, A. A. Mireault, J. R. McAnally, H. Li, E. Sanchez-Ortiz, S. Bhattacharyya, J. M. Shelton, R. Bassel-Duby, E. N. Olson, Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400-403 (2016).
17. C. E. Nelson, C. H. Hakim, D. G. Ousterout, P. I. Thakore, E. A. Moreb, R. M. Castellanos Rivera, S. Madhavan, X. Pan, F. A. Ran, W. X. Yan, A. Asokan, F. Zhang, D. Duan, C. A. Gersbach, In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403-407 (2016).
18. M. Tabebordbar, K. Zhu, J. K. W. Cheng, W. L. Chew, J. J. Widrick, W. X. Yan, C. Maesner, E. Y. Wu, R. Xiao, F. A. Ran, L. Cong, F. Zhang, L. H. Vandenberghe, G. M. Church, A. J. Wagers, In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407-411 (2016).
19. N. E. Bengtsson, J. K. Hall, G. L. Odom, M. P. Phelps, C. R. Andrus, R. D. Hawkins, S. D. Hauschka, J. R. Chamberlain, J. S. Chamberlain, Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun. 8, 14454 (2017).
20. Y. Zhang, C. Long, H. Li, J. R. McAnally, K. K. Baskin, J. M. Shelton, R. Bassel-Duby, E. N. Olson, CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci. Adv. 3, e1602814 (2017).
21. G. L. Walmsley, V. Arechavala-Gomeza, M. Fernandez-Fuente, M. M. Burke, N. Nagel, A. Holder, R. Stanley, K. Chandler, S. L. Marks, F. Muntoni, G. D. Shelton, R. J. Piercy, A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient Cavalier King Charles Spaniels is amenable to exon 51 skipping. PLOS ONE 5, e8647 (2010).
22. A. T. J. M. Helderman-van den Enden, C. S. M. Straathof, A. Aartsma-Rus, J. T. den Dunnen, B. M. Verbist, E. Bakker, J. J. G. M. Verschuuren, H. B. Ginjaar, Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul. Disord. 20, 251-254 (2010).
23. P. A. Romitti, Y. Zhu, S. Puzhankara, K. A. James, S. K. Nabukera, G. K. D. Zamba, E. Ciafaloni, C. Cunniff, C. M. Druschel, K. D. Mathews, D. J. Matthews, F. J. Meaney, J. G. Andrews, K. M. C. Conway, D. J. Fox, N. Street, M. M. Adams, J. Bolen; MD STARnet, Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics 135, 513-521 (2015).
24. R. J. Fairclough, M. J. Wood, K. E. Davies, Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat. Rev. Genet. 14, 373-378 (2013).
25. C. L. Bladen, D. Salgado, S. Monges, M. E. Foncuberta, K. Kekou, K. Kosma, H. Dawkins, L. Lamont, A. J. Roy, T. Chamova, V. Guergueltcheva, S. Chan, L. Korngut, C. Campbell, Y. Dai, J. Wang, N. Barišić, P. Brabec, J. Lahdetie, M. C. Walter, O. Schreiber-Katz, V. Karcagi, M. Garami, V. Viswanathan, F. Bayat, F. Buccella, E. Kimura, Z. Koeks, J. C. van den Bergen, M. Rodrigues, R. Roxburgh, A. Lusakowska, A. Kostera-Pruszczyk, J. Zimowski, R. Santos, E. Neagu, S. Artemieva, V. M. Rasic, D. Vojinovic, M. Posada, C. Bloetzer, P.-Y. Jeannet, F. Joncourt, J. Díaz-Manera, E. Gallardo, A. A. Karaduman, H. Topaloǧlu, R. El Sherif, A. Stringer, A. V. Shatillo, A. S. Martin, H. L. Peay, M. I. Bellgard, J. Kirschner, K. M. Flanigan, V. Straub, K. Bushby, J. Verschuuren, A. Aartsma-Rus, C. Béroud, H. Lochmüller, The TREAT-NMD DMD Global Database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395-402 (2015).
26. Y. Li, Z. Liu, S. OuYang, Y. Zhu, L. Wang, J. Wu, Distribution of dystrophin gene deletions in a Chinese population. J. Int. Med. Res. 44, 99-108 (2016).
27. P. J. Smith, C. Zhang, J. Wang, S. L. Chew, M. Q. Zhang, A. R. Krainer, An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum. Mol. Genet. 15, 2490-2508 (2006).
28. L. Cartegni, J. Wang, Z. Zhu, M. Q. Zhang, A. R. Krainer, ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31, 3568-3571 (2003).
29. L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
30. P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
31. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, E. Charpentier, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
32. C. Zincarelli, S. Soltys, G. Rengo, J. E. Rabinowitz, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080 (2008).
33. M. Martari, A. Sagazio, A. Mohamadi, Q. Nguyen, S. D. Hauschka, E. Kim, R. Salvatori, Partial rescue of growth failure in growth hormone (GH)-deficient mice by a single injection of a double-stranded adeno-associated viral vector expressing the GH gene driven by a muscle-specific regulatory cassette. Hum. Gene Ther. 20, 759-766 (2009).
34. H. Büning, L. Perabo, O. Coutelle, S. Quadt-Humme, M. Hallek, Recent developments in adeno-associated virus vector technology. J. Gene Med. 10, 717-733 (2008).
35. C. S. Young, M. R. Hicks, N. V. Ermolova, H. Nakano, M. Jan, S. Younesi, S. Karumbayaram, C. Kumagai-Cresse, D. Wang, J. A. Zack, D. B. Kohn, A. Nakano, S. F. Nelson, M. C. Miceli, M. J. Spencer, A. D. Pyle, A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18, 533-540 (2016).
36. B. S. Strauss, The "A" rule revisited: Polymerases as determinants of mutational specificity. DNA Repair 1, 125-135 (2002).
37. J. S. Chamberlain, J. B. Jaynes, S. D. Hauschka, Regulation of creatine kinase induction in differentiating mouse myoblasts. Mol. Cell. Biol. 5, 484-492 (1985).
38. J. B. Jaynes, J. S. Chamberlain, J. N. Buskin, J. E. Johnson, S. D. Hauschka, Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts. Mol. Cell. Biol. 6, 2855-2864 (1986).
39. C. Long, J. R. McAnally, J. M. Shelton, A. A. Mireault, R. Bassel-Duby, E. N. Olson, Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184-1188 (2014).
40. A. L. H. Arnett, P. Konieczny, J. N. Ramos, J. Hall, G. Odom, Z. Yablonka-Reuveni, J. R. Chamberlain, J. S. Chamberlain, Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol. Ther. Methods Clin. Dev. 1, 14038 (2014).
41. J. H. van Berlo, J. D. Molkentin, An emerging consensus on cardiac regeneration. Nat. Med. 20, 1386-1393 (2014).
42. Y. Shimizu-Motohashi, S. Miyatake, H. Komaki, S. Takeda, Y. Aoki, Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: From discovery to clinical trials. Am. J. Transl. Res. 8, 2471-2489 (2016).
43. C. A. Stein, Eteplirsen approved for Duchenne muscular dystrophy: The FDA faces a difficult choice. Mol. Ther. 24, 1884-1885 (2016).
44. J. J. Dowling, Eteplirsen therapy for Duchenne muscular dystrophy: Skipping to the front of the line. Nat. Rev. Neurol. 12, 675-676 (2016).
45. A. Aartsma-Rus, A. M. Krieg, FDA approves eteplirsen for Duchenne muscular dystrophy: The next chapter in the eteplirsen saga. Nucleic Acid Ther. 27, 1-3 (2017).
46. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, F. Zhang, Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
47. L. Pinello, M. C. Canver, M. D. Hoban, S. H. Orkin, D. B. Kohn, D. E. Bauer, G.-C. Yuan, Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695-697 (2016).
48. K. Kodippili, L. Vince, J.-H. Shin, Y. Yue, G. E. Morris, M. A. McIntosh, D. Duan, P. McNeil, Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of Duchenne muscular dystrophy by immunostaining and western blot. PLOS ONE 9, e88280 (2014).